Sanmina Corp.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US8010561020
USD
160.76
6.61 (4.29%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Sanmina Corp. stock-summary
stock-summary
Sanmina Corp.
Pharmaceuticals & Biotechnology
Sanmina Corporation is a provider of integrated manufacturing solutions, components, products and repair, logistics and after-market services. The Company provides its offerings primarily to original equipment manufacturers (OEMs) in various industries, including communications networks, storage, industrial, defense and aerospace, medical and energy. The Company operates through two businesses: Integrated Manufacturing Solutions (IMS) and Components, Products and Services (CPS). IMS consists of printed circuit board assembly and test, final system assembly and test, and direct-order-fulfillment. Its Components include interconnect systems and mechanical systems. Its Products include memory, radio frequency (RF), optical and microelectronics solutions, defense and aerospace products, storage solutions and cloud-based manufacturing execution software. Its Services include design, engineering, logistics and repair services.
Company Coordinates stock-summary
Company Details
2700 N 1st St , SAN JOSE CA : 95134-2015
stock-summary
Tel: 1 408 96435001 408 9643610
stock-summary
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 89 Schemes (57.84%)

Foreign Institutions

Held by 138 Foreign Institutions (10.22%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Jure Sola
Chairman of the Board, Chief Executive Officer
Ms. Jacquelyn Ward
Lead Independent Director
Mr. Eugene Delaney
Independent Director
Mr. John Goldsberry
Independent Director
Ms. Rita Lane
Independent Director
Mr. Joseph Licata
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
2,042 Million
(Quarterly Results - Jun 2025)
Net Profit:
73 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 11,620 Million (Small Cap)

stock-summary
P/E

32.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.22

stock-summary
Return on Equity

12.73%

stock-summary
Price to Book

5.07